ViiV Healthcare Trial Meets Primary Endpoint for HIV Treatment
ViiV Healthcare announced that its Phase IIIb CROWN trial met its primary endpoint, showing Cabenuva achieved superior viral suppression compared to daily oral ART at six months in adults and adolescents with detectable HIV-1 viremia. Use in people with viremia is investigational and not approved.